Medical management of brain metastases from lung cancer (Review)

Oncology Reports

Volumn 22, Issue 6, 2009, Pages 1269-1276

  Yamanaka, Ryuya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Brain metastases; Chemotherapy; Lung cancer; Non small cell carcinoma; Small cell carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FOTEMUSTINE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NAVELBINE; PACLITAXEL; TEMOZOLOMIDE; TENIPOSIDE; TOPOTECAN; VINCRISTINE;

BONE MARROW SUPPRESSION; BRAIN METASTASIS; BRAIN SURGERY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; INCIDENCE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MORBIDITY; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RASH; REVIEW; UNSPECIFIED SIDE EFFECT;

ADULT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM METASTASIS; RECURRENCE; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 70449356928     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000564     Document Type: Review

References (87)

1. Kristensen CA, Kristjansen PE and Hansen HH: Systemic chemotherapy of brain metastases from small-cell lung cancer: a review. J Clin Oncol 10: 1498-1502, 1992.
2. Wen PY, McLaren Black P and Loeffler JS: Metastatic brain cancer. In: Cancer: Principles and Practice of Oncology. 6th edition. De Vita VT Jr, Hellman S and Rosenberg SA (eds). Lippincott Williams & Wilkins, Philadelphia, PA, pp2655-2670, 1999.
3. Lagerwaard FJ, Levendag PC, Nowak PJCM, et al: Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 43: 795-803, 1999.
4. Sheenan JP, Sun MH, Kondziolka D, et al: Radiosurgery for non-small cell lung carcinoma metastatic to the brain: long-term outcomes and prognostic factors influencing patient survival time and local tumor control. J Neurosurg 97: 1276-1281, 2002.
5. Stewart DJ, Leavens M, Maor M, et al: Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 42: 2474-2479, 1982.
6. Patchell RA, Tibbs PA, Walsh JW, et al: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322: 494-500, 1990.
7. Kihlström L, Karlsson B and Lindquist C: Gamma Knife surgery for cerebral metastases. Implications for survival based on 16 years experience. Stereotact Funct Neurosurg 61: 45-50, 1993.
8. Horton J, Baxter DH and Olson KB: The management of metastases to the brain by irradiation and corticosteroids. Am J Roentgenol Radium Ther Nucl Med 111: 334-336, 1971.
9. Fukuoka S, Seo Y, Takanashi M, et al: Radiosurgery of brain metastases with the Gamma Knife. Stereotact Funct Neurosurg 66: 193-200, 1996.
10. Siegers HP: Chemotherapy for brain metastases: recent developments and clinical considerations. Cancer Treat Rev 17: 63-76, 1990.
11. Lesser GJ: Chemotherapy of cerebral metastases from solid tumors. Neurosurg Clin N Am 7: 527-536, 1996.
12. Stanley K and Stjernsward J: Lung cancer - a worldwide health problem. Chest 96: S1-S5, 1989.
13. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909, 1995.
14. Schiller JH, Harrington D, Belani CP, et al: Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. New Engl J Med 346: 92-98, 2002.
15. Cotto C, Berille J, Souquet PJ, et al: A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer. Eur J Cancer 32: 69-71, 1996.
16. Malacarne P, Santini A and Maestri A: Response of brain metastases from lung cancer to systemic chemotherapy with carboplatin and etoposide. Oncology 53: 210-213, 1996.
17. Minotti V, Crinò L, Meacci ML, et al: Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer 20: 93-98, 1998.
18. Franciosi V, Cocconi G, Michiara M, et al: Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non-small cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 85: 1599-1605, 1999.
19. Fujita A, Ohkubo T, Hoshino H, et al: Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small cell lung cancer. Br J Cancer 89: 1008-1012, 2003.
20. Robinet G, Thomas P, Breton JL, et al: Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1. Ann Oncol 12: 59-67, 2001.
21. Bernardo G, Cuzzoni Q, Strada MR, et al: First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small cell lung cancer: a phase II study. Cancer Invest 20: 293-302, 2002.
22. Cortes J, Rodriguez J, Aramendia JM, et al: Front-line paclitaxel/ cisplatin-based chemotherapy in brain metastases from non-small cell lung cancer. Oncology 64: 28-35, 2003.
23. Rusch V, Baselga J, Cordon-Cardo C, et al: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53: 2379-2385, 1993.
24. Volm M, Rittgen W and Drings P: Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 77: 663-669, 1998.
25. Lawrence DS and Niu J: Protein kinase inhibitors: the tyrosine-specific protein kinases. Pharmacol Ther 77: 81-114, 1998.
26. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21: 2237-2246, 2003.
27. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 290: 2149-2158, 2003.
28. Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 353: 133-144, 2005.
29. Cappuzzo F, Hirsch FR, Ross E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 97: 643-655, 2005.
30. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
31. Eberhard DA, Johnson BE, Amler LC, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23: 5900-5909, 2005.
32. Chiu CH, Tsai CM, Chen YM, et al: Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 47: 129-138, 2005.
33. Wu C, Li YL, Wang ZM, et al: Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 57: 359-364, 2007.
34. Ceresoli GL, Cappuzzo F, Gregorc V, et al: Gefitinib in patients with brain metastases from non-small cell lung cancer: a prospective trial. Ann Oncol 15: 1042-1047, 2004.
35. Antoniou D, Kyprianou K, Stathopoulos GP, et al: Response to radiotherapy in brain metastases and survival of patients with non-small cell lung cancer. Oncol Rep 14: 733-736, 2005.
36. Nieder C, Niewald M and Hagen T: Brain metastases in bronchial and breast carcinoma: differences in metastatic behavior and prognosis (German). Radiologe 35: 816-821, 1995.
37. Shimato S, Mitsudomi T, Kosaka T, et al: EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neuro Oncol 8: 137-144, 2006.
38. Yokouchi H, Yamazaki K, Kinoshita I, et al: Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer 7: 51, 2007.
39. Sakai M, Ishikawa S, Ito H, et al: Carcinomatous meningitis from non-small cell lung cancer responding to gefitinib. Int J Clin Oncol 11: 243-245, 2006.
40. Kim MK, Lee KH, Lee JK, et al: Gefitinib is also active for carcinomatous meningitis in NSCLC. Lung Cancer 50: 265-269, 2005.
41. Lai CS, Boshoff C, Falzon M and Lee SM: Complete response to erlotinib treatment in brain metastases from recurrent NSCLC. Thorax 61: 91, 2006.
42. Popat S, Hughes S, Papadopoulos P, et al: Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Lung Cancer 56: 135-137, 2007.
43. Chang JW, Chou CL, Huang SF, et al: Erlotinib response of EGFR-mutant gefitinib-resistant non-small cell lung cancer. Lung Cancer 58: 414-417, 2007.
44. Gounant V, Wislez M, Poulot V, et al: Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small cell lung cancer. Lung Cancer 58: 425-428, 2007.
45. Fekrazad MH, Ravindranathan M and Jones DV Jr: Response of intracranial metastases to erlotinib therapy. J Clin Oncol 25: 5024-5026, 2007.
46. Von Pawel J, Wagner H, Duell T and Poellinger B: Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: two case reports. Onkologie 31: 123-126, 2008.
47. Altavilla G, Arrigo C, Santarpia MC, et al: Erlotinib therapy in a patient with non-small cell lung cancer and brain metastases. J Neurooncol 90: 31-33, 2008.
48. Ruppert AM, Beau-Faller M, Neuville A, et al: EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Eur Respir J 33: 436-440, 2009.
49. Pao W and Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small cell lung cancer: current knowledge and future directions. J Clin Oncol 23: 2556-2568, 2005.
50. Baker SD, Wirth M, Statkevich P, et al: Absorption, metabolism and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 5: 309-317, 1999.
51. Ostermann S, Csajka C, Buclin T, et al: Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10: 3728-3736, 2004.
52. Giorgio CG, Giuffrida D, Pappalardo A, et al: Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. Lung Cancer 50: 247-254, 2005.
53. Kouroussis C, Vamvakas L, Vardakis N, et al: Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: a phase II study. Oncology 76: 112-117, 2009.
54. Abrey LE, Olson JD, Raizer JJ, et al: A phase II trial of TMZ for patients with recurrent or progressive brain metastases. J Neuro Oncol 53: 259-265, 2001.
55. Christodoulou C, Bafaloukos D, Kosmidis P, et al: Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 12: 249-254, 2001.
56. D'Atri S, Graziani G, Lacal PM, et al: Attenuation of O6-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells. J Pharmacol Exp Ther 294: 664-671, 2000.
57. Piccioni D, D'Atri S, Papa G, et al: Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. J Chemother 7: 224-229, 1995.
58. Ebert BL, Niemerko E, Shaffer K, et al: Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist 8: 69-75, 2003.
59. Mangiameli A, Mineo G and Trovato G: Temozolomide (TMZ) in patients with brain metastases from NSCLC in combination with brain metastases from NSCLC in combination with gemcitabine-cisplatin (GEM+CDDP) or gemcitabine-vinorelbine (GEM+VNB). Proc Am Soc Clin Oncol 20: A2797, 2001.
60. Quantin X, Khial F, Reme-Saumon M, et al: Concomitant brain radiotherapy and vinorelbine-ifosfamide-cisplatin chemotherapy in brain metastases of non-small cell lung cancer. Lung Cancer 26: 25-39, 1999.
61. Quantin X, Pujol JL, Paris A, et al: Concomitant brain radiotherapy and high-dose ifosfamide in brain relapses of lung cancer. Ann Oncol 8: 911-913, 1997.
62. Ma S, Xu Y, Deng Q and Yu X: Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer 65: 198-203, 2009.
63. Addeo R, De Rosa C, Faiola V, et al: Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for non-small cell lung cancer and breast cancer patients with brain metastases. Cancer 113: 2524-2531, 2008.
64. Cortot AB, Gerinière L, Robinet G, et al: Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small cell lung cancer patients with brain metastases: a GLOT-GFPC study. Ann Oncol 17: 1412-1417, 2006.
65. Antonodau D, Paraskevaidis M, Sarris G, et al: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20: 3644-3650, 2002.
66. Van de Pol M, van Oosterhout AG, Wilmink JT, et al: MRI in detection of brain metastases at initial staging of small-cell lung cancer. Neuroradiology 38: 207-210, 1996.
67. Seute T, Leffers P, Ten Velde GP and Twijnstra A: Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. Cancer 100: 801-806, 2004.
68. Komaki R, Cox JD and Whitson W: Risk of brain metastasis from small cell carcinoma of the lung related to length of survival and prophylactic irradiation. Cancer Treat Rep 65: 811-814, 1981.
69. Arriagada R, Le Chevalier T, Borie F, et al: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 87: 183-190, 1995.
70. Lee JS, Murphy WK, Glisson BS, et al: Primary chemotherapy of brain metastasis in small-cell lung cancer. J Clin Oncol 7: 916-922, 1989.
71. Twelves CJ, Souhami RL, Harper PG, et al: The response of cerebral metastases in small cell lung cancer to systemic chemotherapy. Br J Cancer 61: 147-150, 1990.
72. Kristjansen PE, Soelberg Sørensen P, Skov Hansen M and Hansen HH: Prospective evaluation of the effect on initial brain metastases from small cell lung cancer of platinum-etoposide based induction chemotherapy followed by an alternating multidrug regimen. Ann Oncol 4: 579-583, 1993.
73. Seute T, Leffers P, Wilmink JT, et al: Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J Clin Oncol 24: 2079-2083, 2006.
74. Postmus PE, Haaxma-Reiche H, Sleijfer DT, et al: High-dose etoposide for central nervous system metastases of small cell lung cancer. Preliminary results. Eur J Respir Dis Suppl 149: 65-71, 1987.
75. Groen HJ, Smit EF, Haaxma-Reiche H and Postmus PE: Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer. Eur J Cancer 29: 1696-1699, 1993.
76. Postmus PE, Smit EF, Haaxma-Reiche H, et al: Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 13: 660-665, 1995.
77. Schütte W, Manegold C, von Pawel JV, et al: Topotecan - a new treatment option in the therapy of brain metastases of lung cancer. Front Radiat Ther Oncol 33: 354-363, 1999.
78. Postmus PE, Haaxma-Reiche H, Smit EF, et al: Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy - a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Onol 18: 3400-3408, 2000.
79. Korfel A, Oehm C, von Pawel J, et al: Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. a multicentre phase II study. Eur J Cancer 38: 1724-1729, 2002.
80. Chen G, Huynh M, Chen A, et al: Chemotherapy for metastases in small-cell lung cancer. Clin Lung Cancer 9: 35-38, 2008.
81. Régina A, Demeule M, Laplante A, et al: Multidrug resistance in brain tumors: roles of the blood brain barrier. Cancer Metastasis Rev 20: 13-25, 2001.
82. Postmus PE and Smit EF: Chemotherapy for brain metastases of lung cancer: a review. Ann Oncol 10: 753-759, 1999.
83. Bunn PA Jr, Nugent JL and Matthews MJ: Central nervous system metastases in small cell bronchogenic carcinoma. Semin Oncol 5: 314-322, 1978.
84. Neijstrom ES, Capizzi RL, Rudnick SA, et al: High-dose methotrexate in small cell lung cancer. Lack of efficacy in preventing CNS relapse. Cancer 51: 1056-1061, 1983.
85. Van den Bent MJ: The role of chemotherapy in brain metastases. Eur J Cancer 39: 2114-2120, 2003.
86. McCune JS, Hawke RL, Le Cluyse EL, et al: In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 68: 356-366, 2000.
87. Yap KY, Chui WK and Chan A: Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther 30: 1385-1407, 2008.